Effects of Indacaterol maleate and Glycopyrronium bromide combined with Budesonide in treatment of patients with chronic obstructive pulmonary disease
Objective:To observe effects of Indacaterol maleate and Glycopyrronium bromide combined with Budesonide in treatment of patients with chronic obstructive pulmonary disease(COPD).Methods:The clinical data of 68 patients with COPD admitted to this hospital from June 2022 to April 2024 were retrospectively analyzed.According to different treatment schemes,they were divided into control group and observation group,34 cases in each group.The control group was treated with Budesonide suspension aerosol inhalation,while the observation group was treated with Indacaterol maleate and Glycopyrronium bromide on the basis of that of the control group.The levels of pulmonary function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/FVC],inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP)]and blood gas analysis indexes[arterial partial pressure of oxygen(PaO2),arterial oxygen saturation(SaO2),arterial partial pressure of carbon dioxide(PaCO2)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of FEV1,FVC and FEV1/FVC in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-6,IL-8,TNF-α and hs-CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of PaO2 and SaO2 in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the PaCO2 levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Indacaterol maleate and Glycopyrronium bromide combined with Budesonide in the treatment of the COPD patients can improve the levels of lung function indexes,improve the levels of blood gas analysis indexes,and reduce the levels of inflammatory factors.Moreover,it is superior to simple Budesonide suspension aerosol inhalation.
Indacaterol maleate and Glycopyrronium bromideBudesonideChronic obstructive pulmonary diseaseLung functionBlood gas analysisInflammatory factorAdverse reaction
万方数据
维普
